Skip to main content

OptiBiotix Health plc sign up human studies with Reading University

OptiBiotix Health plc sign up human studies with Reading University

Seneca investee company, OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has signed an agreement with the University of Reading for the commencement of human studies on its first product, a capsular food supplement to reduce cholesterol. This is in addition to the successful early studies on the Company’s weight management formulation in yoghurts, announced at the end of October 2014.

See the article in full at directorstalk.com